Cargando…
Palmitoyl Serotonin Inhibits L-dopa-induced Abnormal Involuntary Movements in the Mouse Parkinson Model
L-3,4-dihydroxyphenylalanine (L-DOPA) is the most common treatment for patients with Parkinson's disease (PD). However, long term use of L-DOPA for PD therapy lead to abnormal involuntary movements (AIMs) known as dyskinesia. Fatty acid amide hydrolase (FAAH) is enriched protein in basal gangli...
Autores principales: | Park, Hye-Yeon, Ryu, Young-Kyoung, Go, Jun, Son, Eunjung, Kim, Kyoung-Shim, Kim, Mee Ree |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society for Brain and Neural Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4999423/ https://www.ncbi.nlm.nih.gov/pubmed/27574484 http://dx.doi.org/10.5607/en.2016.25.4.174 |
Ejemplares similares
-
β-Lapachone ameliorates L-DOPA-induced dyskinesia in a 6-OHDA-induced mouse model of Parkinson's disease
por: Ryu, Young-Kyoung, et al.
Publicado: (2021) -
Dopaminergic co-transmission with sonic hedgehog inhibits abnormal involuntary movements in models of Parkinson’s disease and L-Dopa induced dyskinesia
por: Malave, Lauren, et al.
Publicado: (2021) -
Striatal ΔFosB gene suppression inhibits the development of abnormal involuntary movements induced by L-Dopa in rats
por: Beck, Goichi, et al.
Publicado: (2021) -
Assessment of abnormal involuntary movements in psychiatric patients.
por: Jaitpal, Varun, et al.
Publicado: (2022) -
Riluzole Attenuates L-DOPA-Induced Abnormal Involuntary Movements Through Decreasing CREB1 Activity: Insights from a Rat Model
por: Pagliaroli, Luca, et al.
Publicado: (2018)